Vicarious Surgical Demonstrates Sustained System Performance and Complex Hernia Procedure Workflows in Pre-Clinical Setting
Rhea-AI Summary
Vicarious Surgical (OTCQB: RBOT) reported a full-day synthetic abdominal model lab for the Vicarious Surgical System, showing sustained system performance and complex ventral hernia procedure workflows (IPOM+ and rTAPP) using its integrated instrument suite.
The testing extended prior benchtop work into clinically relevant conditions, with progress in runtime stability, visualization, instrument control and workflow execution. The company reiterates it remains on track for a design freeze by end of 2026 and plans further cadaveric and in-vivo studies.
AI-generated analysis. Not financial advice.
Positive
- Full-day synthetic abdominal lab showed sustained Vicarious Surgical System performance
- Completion of back-to-back IPOM+ and rTAPP ventral hernia workflows
- Use of integrated instrument suite under fully draped operating conditions
- Progress in runtime stability, visualization, instrument control and workflow execution
- Milestone advances system toward design freeze targeted by end of 2026
- Planned expansion of workflow testing for ventral hernia and other abdominal procedures
Negative
- Testing remains in pre-clinical synthetic models, not yet cadaveric or in-vivo
- Clinical readiness still dependent on future cadaveric and in-vivo studies
Key Figures
Market Reality Check
Peers on Argus
Two Argus-tracked peers, IINN and NMTC, also appeared in the momentum scanner, both moving down (median move -9.3%), indicating broader weakness across related medical device names alongside RBOT’s -5% move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Q1 2026 earnings | Positive | -9.1% | Reported sharply lower operating expenses and narrower net loss versus prior year. |
| Mar 30 | Tech milestone | Positive | -4.6% | Completed integrated benchtop testing of full instrument suite for ventral hernia repair. |
| Mar 25 | OTCQB quotation | Positive | -5.6% | Began OTCQB quotation as part of strategic path toward potential Nasdaq listing. |
| Mar 16 | Nasdaq plan | Positive | +29.4% | Outlined strategic plan to pursue Nasdaq listing and reduced 2026 cash burn guidance. |
| Mar 09 | FY 2025 earnings | Positive | +24.3% | Reported reduced expenses, narrower losses, and 2026 cash burn expected around $19M. |
Operational and product development updates have often been followed by negative moves, while broader strategic and financing updates in March 2026 saw strong positive reactions.
Over the last six months, Vicarious Surgical has focused on cost control, capital market positioning, and progressing its robotic platform. Earnings in Q4 2025 and Q1 2026 highlighted sharply lower operating expenses and reduced cash burn, but only the March 9 and March 16 strategic updates on Nasdaq relisting, financing, and cash runway drew strong positive price reactions. By contrast, the March 30 integrated benchtop testing milestone and other operational news saw share price declines, suggesting a mixed history of how development milestones translate into near-term trading.
Regulatory & Risk Context
An effective S-3 shelf filed on 2025-12-12 allows Vicarious Surgical to issue up to $100,000,000 in various securities over time, including an at-the-market program for up to $3,000,000 of Class A common stock, which can be used to fund development and operations but also introduces ongoing dilution capacity.
Market Pulse Summary
This announcement highlights continued de-risking of the Vicarious Surgical System via sustained, fully draped operation and complex ventral hernia workflows in a synthetic model, supporting a design-freeze goal by end of 2026. In recent months, the company has combined cost reductions with capital market and listing initiatives, plus an effective $100,000,000 shelf for future funding. Investors may focus on progression to cadaveric and in‑vivo studies and any subsequent financing steps as key markers of execution.
Key Terms
ventral hernia repair medical
monopolar scissors medical
electrosurgical energy medical
AI-generated analysis. Not financial advice.
Company Remains on Track For Design Freeze by End of Year 2026
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced the successful completion of a full-day synthetic abdominal model lab demonstrating sustained system performance and continued procedural workflow progression for the Vicarious Surgical System.
During the lab, the Vicarious Surgical System operated fully draped for multiple hours while our CMO, Dr. Barry Greene, an experienced abdominal surgeon, performed back-to-back IPOM+ and robotic transabdominal preperitoneal (rTAPP) ventral hernia repair workflows. The lab was conducted using the Company’s integrated instrument suite, including needle drivers, graspers, monopolar scissors and electrosurgical energy.
The lab represents an important progression beyond the Company’s previously announced integrated benchtop testing milestone by extending validation of the Vicarious Surgical System into sustained procedural workflows under clinically relevant operating conditions. The testing demonstrated continued progress in runtime stability, visualization, instrument control and workflow execution as the Company advances toward design freeze and future cadaveric and in-vivo studies.
“Our recent synthetic lab represented another important step forward in the systematic de-risking of the Vicarious Surgical System,” said Stephen From, Chief Executive Officer of Vicarious Surgical. “Demonstrating sustained operation under fully draped conditions while successfully completing increasingly complex procedural workflows using our integrated instrument suite reinforces our confidence in the progress of the platform and our path toward design freeze and future clinical readiness.”
The Company intends to continue expanding procedural workflow testing and system validation activities as it advances development of the Vicarious Surgical System for ventral hernia repair and other abdominal procedures.
About Vicarious Surgical
Founded in 2014, Vicarious Surgical is a next-generation surgical robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and has received backing by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.
In accordance with guidance provided by the SEC regarding use by a company of its websites and social media channels as a means to disclose material information to investors and to comply with its disclosure obligations under Regulation FD, the Company hereby notifies investors, the media and other interested parties that it intends to continue to use its investor relations website (https://investor.vicarioussurgical.com/), its LinkedIn page (https://linkedin.com/company/vicarious-surgical/) and its X feed (@VicariousSurg) to publish important information about the Company, including information that may be deemed material to investors. The list of social media channels that the Company uses may be updated on its investor relations website from time to time. The Company encourages investors, the media, and other interested parties to review the information the Company posts on its website and social media channels as described above, in addition to information announced by the Company through its SEC filings, press releases and public conference calls and webcasts.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, including without limitation, statements regarding the timeline for design freeze for the Vicarious Surgical System, the Company’s intention to list its Class A common stock on the Nasdaq Capital Market, the anticipated benefits of quotation on the OTCQB Venture Market such as market visibility, market maker participation and enhanced trading liquidity, and the potential to re-engage with a broader investor base, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the Company’s ability to obtain and maintain listing on a national securities exchange; the impacts of the Company’s reduced cash burn; the price of the Class A common stock following any reverse stock split; the Company’s future business strategy; the approval, commercialization and adoption of the Company’s initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product and service development activities; the potential attributes and benefits of the Company’s product candidates and services; the Company’s ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing license, manufacture, supply and distribution agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; economic downturns, political and market conditions and their potential to adversely affect the Company’s business, financial condition and results of operations; the Company’s intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in the Company’s filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Investor Contact
ir@vicarioussurgical.com
Media Inquiries
media@vicarioussurgical.com
Source: Vicarious Surgical Inc.
